PILA — Pila Pharma AB Income Statement
0.000.00%
- SEK86.53m
- SEK81.64m
- SEK0.77m
Annual income statement for Pila Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.719 | 1.88 | 1.46 | 0.775 |
Cost of Revenue | |||||
Gross Profit | -0.492 | 0.681 | 1.88 | -1.87 | -5.91 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 6.98 | 17.9 | 28.7 | 11.4 | 12 |
Operating Profit | -6.98 | -17.2 | -26.8 | -9.89 | -11.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.98 | -17.2 | -26.8 | -9.93 | -11.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.98 | -17.2 | -26.8 | -9.93 | -11.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.98 | -17.2 | -26.8 | -9.93 | -11.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.98 | -17.2 | -26.8 | -9.93 | -11.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.205 | -0.713 | -0.515 | -0.305 | -0.321 |
Dividends per Share |